Scott Halsted, Managing Director

Mr. Halsted is currently a Managing Director for Saints. Mr. Halsted has over 20 years of investment experience in the health care field. Prior to joining Saints, from 1987-2007 he was a managing member of Morgan Stanley Ventures where he was responsible for making growth equity investments in emerging health care companies. As co-head of the health practice, Mr. Halsted oversaw over $300 million of investments in over 40 companies.

Mr. Halsted has served on seventeen Boards of Directors including both private and public companies. Currently, Mr. Halsted is a board member at Endoscopic Technologies and Epitek and a board observer at Reva Medical and DiscoveRx. Illustrative investments include Arcadian Health Management, Benefitmall (acquired by Allied Capital), Cytyc (acquired by Hologic), Emphasys, Idec Pharmaceutical (merged with Biogen), Intuitive Surgical (ISRG), Microgenics (acquired by Sybron), Milestone Healthcare (acquired by HCR), Neurex (acquired by Elan), and R2 Technology (acquired by Hologic).

Prior to his investment career, Mr. Halsted worked in the medical technology field in the areas of product design and business development for Intermedics Orthopedics and Hexcel Medical.

Mr. Halsted holds an AB degree from Dartmouth College as well as a BE degree in biomechanical engineering from the Thayer School of Engineering at Dartmouth College . He also holds an MM degree from Northwestern University.